Novel treatments for immune thrombocytopenia

Presse Medicale

Volumn 43, Issue 4P2, 2014, Pages

  Shih, Andrew ^a   Nazi, Ishac ^a   Kelton, John G ^a   Arnold, Donald M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; AUTOANTIGEN; AVATROMBOPAG; CD40 ANTIGEN; CD40 LIGAND; DEXAMETHASONE; FC RECEPTOR; FOSTAMATINIB; GMA 161; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 23A11; PLACEBO; RHESUS D ANTIBODY; ROZROLIMUPAB; RUPLIZUMAB; SM 101; TORALIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BINDING AFFINITY; BINDING SITE; CLINICAL EFFECTIVENESS; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOLYSIS; HEMOLYTIC ANEMIA; HOT FLUSH; HUMAN; HUMORAL IMMUNITY; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; MEGAKARYOCYTE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; SHORT SURVEY; SIGNAL TRANSDUCTION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; AUTOANTIBODIES; BLOOD PLATELETS; CD40 LIGAND; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; T-LYMPHOCYTES;

EID: 84898836551     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2014.02.006     Document Type: Short Survey

References (87)

1. Lee M.S., Kim W.C. Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis. Neurology 1998, 50:1160-1163.
2. Nørgaard M., Jensen A.Ø., Engebjerg M.C., Farkas D.K., Thomsen R.W., Cha S., et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood 2011, 117:3514-3520.
3. Kühne T., Berchtold W., Michaels L.A., Wu R., Donato H., Espina B., et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica 2011, 96:1831-1837.
4. Portielje J.E., Westendorp R.G., Kluin-Nelemans H.C., Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001, 97:2549-2554.
5. McMillan R., Bussel J.B., George J.N., Lalla D., Nichol J.L. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008, 83:150-154.
6. Kuter D.J., Mathias S.D., Rummel M., Mandanas R., Giagounidis A.A., Wang X., et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol 2012, 87:558-561.
7. Harrington W.J., Sprague C.C., Minnich V., Moore C.V., Aulvin R.C., Dubach R. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern med 1953, 38:433-469.
8. Van Leeuwen E.F., Van Der Ven J.T., Engelfriet C.P., Von Dem Borne A.E. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982, 59:23-26.
9. Stasi R., Cooper N., Del Poeta G., Stipa E., Laura Evangelista M., Abruzzese E., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
10. Ling Y., Cao X., Yu Z., Ruan C. Circulating dendritic cells subsets and CD4+ Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007, 79:310-316.
11. Olsson B., Andersson P.O., Jernas M., Jacobsson S., Carlsson B., Carlsson L.M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003, 9:1123-1124.
12. Zhang F., Chu X., Wang L., Zhu Y., Li L., Ma D., et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006, 76:427-431.
13. Kappler J.W., Staerz U., White J., Marrack P.C. Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex. Nature 1988, 332:35-40.
14. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997, 15:821-850.
15. Chambers C.A. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001, 22:217-223.
16. Jiang H., Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest 2004, 114:1198-1208.
17. Chang M., Nakagawa P.A., Williams S.A., Schwartz M.R., Imfeld K.L., Buzby J.S., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
18. McMillan R., Longmire R.L., Yelenosky R., Donnell R.L., Armstrong S. Quantitation of platelet-binding IgG produced in vitro by spleens from patients with idiopathic thrombocytopenic purpura. N Engl J Med 1974, 291:812-817.
19. Clarkson S.B., Bussel J.B., Kimberly R.P., Valinsky J.E., Nachman R.L., Unkeless J.C. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med 1986, 314:1236-1239.
20. Podolanczuk A., Lazarus A.H., Crow A.R., Grossbard E., Bussel J.B. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009, 113:3154-3160.
21. Ballem P.J., Segal G.M., Stratton J.R., Gernsheimer T., Adamson J.W., Slichter S.J. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987, 80:33-40.
22. Cheng G., Saleh M.N., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377:393-402.
23. Warner M.N., Moore J.C., Warkentin T.E., Santos A.V., Kelton J.G. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999, 104:442-447.
24. McMillan R., Wang L., Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003, 1:485-491.
25. Olsson B., Ridell B., Carlsson L., Jacobsson S., Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008, 112:1078-1084.
26. Chow L., Aslam R., Speck E.R., Kim M., Cridland N., Webster M.L., et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010, 115:1247-1253.
27. Liu B., Zhao H., Poon M.C., Han Z., Gu D., Xu M., et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007, 78:139-143.
28. Bao W., Bussel J.B., Heck S., He W., Karpoff M., Boulad N., et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010, 116:4639-4645.
29. Stasi R., Stipa E., Masi M., Cecconi M., Scimò M.T., Oliva F., et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995, 98:436-442.
30. Neunert C., Lim W., Crowther M., Cohen A., Solberg L., Crowther M.A. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011, 117:4190-4207.
31. Mazzucconi M.G., Fazi P., Bernasconi S., De Rossi G., Leone G., Gugliotta L., et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007, 109:1401-1407.
32. Arnold D.M., Nazi I., Santos A., Chan H., Heddle N.M., Warkentin T.E., et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood 2010, 115:29-31.
33. Arnold D.M., Dentali F., Crowther M.A., Meyer R.M., Cook R.J., Sigouin C., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007, 146:25-33.
34. Patel V.L., Mahevas M., Lee S.Y., Stasi R., Cunningham-Rundles S., Godeau B., et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012, 119:5989-5995.
35. Kojouri K., Vesely S.K., Terrell D.R., George J.N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004, 104:2623-2634.
36. Stasi R., Bosworth J., Rhodes E., Shannon M.S., Willis F., Gordon-Smith E.C. Thrombopoietic agents. Blood Rev 2010, 24:179-190.
37. Kuter D.J., Bussel J.B., Lyons R.M., Pullarkat V., Gernsheimer T.B., Senecal F.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008, 371:395-403.
38. Bussel J.B., Provan D., Shamsi T., Cheng G., Psaila B., Kovaleva L., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:641-648.
39. Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013, 161:411-423.
40. Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013, 121:537-545.
41. Siegal D., Crowther M., Cuker A. Thrombopoietin receptor agonists in primary immune thrombocytopenia. Semin Hematol 2013, 50(Suppl.1):S18-S21.
42. Sprague D.L., Elzey B.D., Crist S.A., Waldschmidt T.J., Jensen R.J., Ratliff T.L. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008, 111:5028-5036.
43. Datta S.K., Kalled S.L. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum 1997, 40:1735-1745.
44. Kuwana M., Nomura S., Fujimura K., Nagasawa T., Muto Y., Kurata Y., et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004, 103:1229-1236.
45. Patel V.L., Schwartz J., Bussel J.B. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008, 141:545-548.
46. Kawai T., Andrews D., Colvin R.B., Sachs D.H., Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000, 6:114.
47. Mirabet M., Barrabes J.A., Quiroga A., Garcia-Dorado D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol 2008, 45:937-944.
48. Debre M., Bonnet M.C., Fridman W.H., Carosella E., Philippe N., Reinert P., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993, 342:945-949.
49. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
50. Flaherty M.M., MacLachlan T.K., Troutt M., Magee T., Tuaillon N., Johnson S., et al. Nonclinical evaluation of GMA161--an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol Sci 2012, 125:299-309.
51. Frandsen T.P., Naested H., Rasmussen S.K., Hauptig P., Wiberg F.C., Rasmussen L.K., et al. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011, 108:2171-2181.
52. Robak T., Windyga J., Trelinski J., von Depka Prondzinski M., Giagounidis A., Doyen C., et al. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood 2012, 120:3670-3676.
53. Kyttaris V.C., Tsokos G.C. Syk kinase as a treatment target for therapy in autoimmune diseases. Clin Immunol 2007, 124:235-237.
54. Greuber E.K., Pendergast A.M. Abl family kinases regulate FcgammaR-mediated phagocytosis in murine macrophages. J Immunol 2012, 189:5382-5392.
55. Muta T., Kurosaki T., Misulovin Z., Sanchez M., Nussenzweig M.C., Ravetch J.V. A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 1994, 368:70-73.
56. Konstaninova T.S., Leonidovna I.V., Hellmann A., et al. Interim results from a phase Ib/IIa clinical trial with the soluble Fc-Gamma IIb receptor SM101 for the treatment of primary immune thrombocytopenia. Blood 2012, 120. [Abstract 3388].
57. Desjardins R.E., Tempel D.L., Lucek R., Kuter D.J. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006, 108. [Abstract 477].
58. Bussel J., Zhang Y., Tang S., McIntosh J., Kuter D. A phase II 6-month extension study of the efficacy, safety, and tolerability of E5501 (AKR501) in subjects with chronic immune thrombocytopenia (CITP). Haematologica 2011, 96. [Abstract 0221].
59. Kuter D.J. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 2013, 98:10-23.
60. Peeters K., Loyen S., Van Kerckhoven S., Stoffels K., Hoylaerts M.F., Van Geet C., et al. Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. Br J Haematol 2010, 151:54-61.
61. Santini V., Giles F.J. The potential of amifostine: from cytoprotectant to therapeutic agent. Haematologica 1999, 84:1035-1042.
62. Fan H., Zhu H.L., Li S.X., Lu X.C., Zhai B., Guo B., et al. Efficacy of amifostine in treating patients with idiopathic thrombocytopenia purpura. Cell Biochem Biophys 2011, 59:7-12.
63. Fan H., Zhu H.L., Li S.X., Lu X.C., Yang Y., Yao S.Q. [Therapy of 17 cases of idiopathic thrombocytopenia purpura by amifostine]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008, 16:192-196.
64. Roopenian D.C., Christianson G.J., Sproule T.J., Brown A.C., Akilesh S., Jung N., et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003, 170:3528-3533.
65. Liu L., Garcia A.M., Santoro H., Zhang Y., McDonnell K., Dumont J., et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol 2007, 178:5390-5398.
66. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
67. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
68. McMinn J.R., Cohen S., Moore J., Lilly S., Parkhurst J., Tarantino M.D., et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol 2003, 73:135-140.
69. Litinskiy M.B., Nardelli B., Hilbert D.M., He B., Schaffer A., Casali P., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
70. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
71. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
72. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
73. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
74. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol 2010, 22:732-739.
75. Harvey P.R., Gordon C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs 2013, 27:85-95.
76. Manzi S., Sanchez-Guerrero J., Merrill J.T., Furie R., Gladman D., Navarra S.V., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two-phase III trials. Ann Rheum Dis 2012, 71:1833-1838.
77. Ginzler E.M., Wax S., Rajeswaran A., Copt S., Hillson J., Ramos E., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012, 14:R33.
78. Semple J.W., Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991, 78:2619-2625.
79. Filion M.C., Bradley A.J., Devine D.V., Decary F., Chartrand P. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur J Immunol 1995, 25:3123-3127.
80. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998, 102:1393-1402.
81. Kuwana M., Okazaki Y., Kaburaki J., Kawakami Y., Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002, 168:3675-3682.
82. Larche M., Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005, 11:S69-S76.
83. Sukati H., Watson H.G., Urbaniak S.J., Barker R.N. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood 2007, 109:4528-4538.
84. Liu G.Y., Fairchild P.J., Smith R.M., Prowle J.R., Kioussis D., Wraith D.C. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995, 3:407-415.
85. Fairchild P.J., Wraith D.C. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today 1996, 17:80-85.
86. Ghadaki B., Nazi I., Kelton J.G., Arnold D.M. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013, [doi:10.1111/trf.12139. Epub ahead of print].
87. Thachil J., Salter I., George J.N. Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim. Eur J Haematol 2013, 91:376-377.